{"id":3420,"date":"2018-10-16T15:33:56","date_gmt":"2018-10-16T10:03:56","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=3420"},"modified":"2024-09-18T15:13:03","modified_gmt":"2024-09-18T09:43:03","slug":"notizia-76","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/notizia-76","title":{"rendered":"Notizia"},"content":{"rendered":"

FDA approves expanded label for Xarelto of Johnson & Johnson<\/strong><\/p>\n

The Food and Drug Administration<\/strong> permitted labelling of blood<\/a> thinner<\/strong>, Xarelto<\/strong> of Johnson & Johnson<\/strong>, as it can decrease the risk of major cardiovascular events in patients with peripheral<\/a> artery disease or chronic coronary artery<\/strong> disease (CAD or PAD). For these conditions, Xarelto (rivaroxaban tablets<\/strong>) is used in combination with aspirin<\/strong>. The call is taken on the basis of\u00a0data from the Phase 3 COMPASS trial<\/strong> that indicated\u00a0Xarelto with aspirin decreased stroke by 42%, cardiovascular death by 22% and heart attack by 14% compared with aspirin alone in this patient group.<\/p>\n

Alnylam go slow\u00a0on accelerated approval for givosiran<\/strong><\/p>\n

The Cambridge, Massachusetts-based drugmaker, Alnylam Pharmaceuticals, <\/strong>focused\u00a0on\u00a0RNA interference therapeutics for genetically defined diseases will go slow on its accelerated approval application for givosiran<\/strong>, an RNAi therapy after having discussions with the Food and Drug Administration. The drugmaker has to wait for full results from a Phase 3 trial<\/strong> that is testing givosiran as a therapy for severe rare diseases called acute hepatic<\/a> porphyrias (AHP)<\/strong>.<\/p>\n

Laser technique might be an option for finger prick test<\/strong><\/p>\n

The researchers at the Massachusetts Institute of Technology and the University Of Missouri School Of Medicine<\/strong> has developed a possible alternative to the finger prick test for measuring blood glucose levels. A process known as Raman spectroscopy<\/strong> is used to diagnose blood glucose levels through the skin. A diabetic person would need to wear a wristband connected to a fiberoptic cable, which uses laser light to evaluate fat tissue, protein, collagen and glucose molecules in the skin. The device then develops a \u201cmolecular fingerprint\u201d<\/strong> based on changes in wavelengths that show different glucose levels.<\/p>\n

Fasting Glycemic Variability shows Increased Risk for Type 2 Diabetes<\/strong><\/p>\n

A great\u00a0variation of fasting plasma glucose over time is related to an increased risk of developing type 2 diabetes<\/a>. The research was done on 131,744 participants without diabetes at baseline for fasting plasma glucose levels and the development of type 2 diabetes. Then researchers analysed data from the Korean National Health Insurance System<\/strong>. The database included information like medical history, ICD-10 codes, health-related variables, questionnaires, blood work analysis, and laboratory testing. Type 2 diabetes was defined as a fasting glucose plasma level \u22657 mmol\/L, and impaired glucose was defined as a fasting glucose plasma level between 5.6 mmol\/L and 6.9 mmol\/L.<\/p>\n","protected":false},"excerpt":{"rendered":"

FDA approves expanded label for Xarelto of Johnson & Johnson The Food and Drug Administration permitted labelling of blood thinner, Xarelto of Johnson & Johnson, as it can decrease the risk of major cardiovascular events in patients with peripheral artery disease or chronic coronary artery disease (CAD or PAD). For these conditions, Xarelto (rivaroxaban tablets) […]<\/p>\n","protected":false},"author":1,"featured_media":3440,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[1990,1482,1988,1984,1989,341,1993,1992,1987,1985],"industry":[17225],"therapeutic_areas":[17240,17239,17228],"class_list":["post-3420","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-acute-hepatic-porphyrias-ahp","tag-alnylam-pharmaceuticals","tag-aspirin","tag-blood-thinner","tag-givosiran","tag-johnson-johnson","tag-molecular-fingerprint","tag-raman-spectroscopy","tag-rivaroxaban-tablets","tag-xarelto","industry-pharmaceutical","therapeutic_areas-endocrinology-and-metabolic-disorders","therapeutic_areas-gastroenterology","therapeutic_areas-oncology"],"acf":[],"yoast_head":"\nNotizia 16\/10\/2018 - DelveInsight Business Research LLP<\/title>\n<meta name=\"description\" content=\"Xarelto can decrease the risk of major cardiovascular events in patients with peripheral artery disease or chronic coronary artery disease...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-76\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Notizia 16\/10\/2018 - DelveInsight Business Research LLP\" \/>\n<meta property=\"og:description\" content=\"Xarelto can decrease the risk of major cardiovascular events in patients with peripheral artery disease or chronic coronary artery disease...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/notizia-76\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-10-16T10:03:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-18T09:43:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/10\/09022443\/UP2.png\" \/>\n\t<meta property=\"og:image:width\" content=\"583\" \/>\n\t<meta property=\"og:image:height\" content=\"310\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Notizia 16\/10\/2018 - DelveInsight Business Research LLP","description":"Xarelto can decrease the risk of major cardiovascular events in patients with peripheral artery disease or chronic coronary artery disease...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/notizia-76","og_locale":"en_US","og_type":"article","og_title":"Notizia 16\/10\/2018 - DelveInsight Business Research LLP","og_description":"Xarelto can decrease the risk of major cardiovascular events in patients with peripheral artery disease or chronic coronary artery disease...","og_url":"https:\/\/www.delveinsight.com\/blog\/notizia-76","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-10-16T10:03:56+00:00","article_modified_time":"2024-09-18T09:43:03+00:00","og_image":[{"width":583,"height":310,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/10\/09022443\/UP2.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-76","url":"https:\/\/www.delveinsight.com\/blog\/notizia-76","name":"Notizia 16\/10\/2018 - DelveInsight Business Research LLP","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-76#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-76#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/10\/09022443\/UP2.png","datePublished":"2018-10-16T10:03:56+00:00","dateModified":"2024-09-18T09:43:03+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Xarelto can decrease the risk of major cardiovascular events in patients with peripheral artery disease or chronic coronary artery disease...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/notizia-76"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-76#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/10\/09022443\/UP2.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/10\/09022443\/UP2.png","width":583,"height":310,"caption":"Hot flashes"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/10\/09022443\/UP2-300x160.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">acute hepatic porphyrias (AHP)<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Alnylam Pharmaceuticals<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">aspirin<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">blood thinner<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">givosiran<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Johnson & Johnson<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">molecular fingerprint\u201d<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Raman spectroscopy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">rivaroxaban tablets<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Xarelto<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">acute hepatic porphyrias (AHP)<\/span>","<span class=\"advgb-post-tax-term\">Alnylam Pharmaceuticals<\/span>","<span class=\"advgb-post-tax-term\">aspirin<\/span>","<span class=\"advgb-post-tax-term\">blood thinner<\/span>","<span class=\"advgb-post-tax-term\">givosiran<\/span>","<span class=\"advgb-post-tax-term\">Johnson & Johnson<\/span>","<span class=\"advgb-post-tax-term\">molecular fingerprint\u201d<\/span>","<span class=\"advgb-post-tax-term\">Raman spectroscopy<\/span>","<span class=\"advgb-post-tax-term\">rivaroxaban tablets<\/span>","<span class=\"advgb-post-tax-term\">Xarelto<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Oct 16, 2018","modified":"Updated on Sep 18, 2024"},"absolute_dates_time":{"created":"Posted on Oct 16, 2018 3:33 pm","modified":"Updated on Sep 18, 2024 3:13 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3420","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=3420"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3420\/revisions"}],"predecessor-version":[{"id":29624,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/3420\/revisions\/29624"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/3440"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=3420"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=3420"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=3420"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=3420"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=3420"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}